Complete Genomics Announces Pricing of Initial Public Offering
November 11 2010 - 9:50AM
Complete Genomics, Inc. (Nasdaq:GNOM) announced the pricing of its
initial public offering of 6,000,000 shares of its common stock at
$9.00 per share. Complete Genomics has granted the underwriters a
30-day option to purchase up to 900,000 additional shares at the
initial public offering price, less the underwriting discounts and
commissions, to cover overallotments, if any. Complete Genomics'
common stock will be listed on the NASDAQ Global Market under the
symbol "GNOM" and will begin trading today, Thursday, November 11,
2010. All of the shares in the offering are being offered by
Complete Genomics.
UBS Investment Bank and Jefferies & Company are
acting as joint book-running managers for the offering, with Baird
and Cowen and Company acting as co-managers.
A registration statement relating to these
securities has been filed with, and declared effective by, the
Securities and Exchange Commission. This press release shall
neither constitute an offer to sell nor a solicitation of an offer
to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
This offering will be made only by means of a
prospectus. Copies of the preliminary prospectus or, when
available, the final prospectus, for this offering may be obtained
from the prospectus department of UBS Investment Bank at 299 Park
Avenue, New York, NY 10171, Attention: Prospectus Department or
from Equity Syndicate Prospectus Department, Jefferies &
Company, 520 Madison Avenue, 12th Floor, New York, NY 10022, at
877-547-6340, and at Prospectus_Department@Jefferies.com.
About Complete Genomics
Complete Genomics is a life sciences company that
has developed and commercialized an innovative DNA sequencing
platform. The Complete Genomics Analysis Platform (CGA™ Platform)
combines Complete Genomics' proprietary human genome sequencing
technology with its advanced informatics and data management
software and its innovative, end-to-end, outsourced service model
to provide customers with data that is immediately ready to be used
for genome-based research.
The Complete Genomics logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8216
CONTACT: Complete Genomics, Inc.
Investor Relations
Scott Sandler
(650) 943-2788
ssandler@completegenomics.com
Jennifer Turcotte, Vice President of Marketing
(650) 943-2846
jturcotte@completegenomics.com
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Aug 2023 to Aug 2024